AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11085661 — intervention group
Group type: EXPERIMENTAL
Intervention: Seborrheic dermatitis (17.4% of allergic skin diseases)
Number of subjects: 1000
Study 9069482 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with epilepsy during childhood
Number of subjects: 81
Study 9069482 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 81
Study 8347333 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine 2 mg q2h while awake for 7 days plus yohimbine 10 mg and 20 mg challenges
Number of subjects: 10
Study 8347333 — intervention group
Group type: COMPARATOR
Intervention: Placebo q2h while awake for 5 days plus yohimbine 10 mg and 20 mg challenges
Number of subjects: 10
Study 8347333 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine plus yohimbine
Number of subjects: 10
Study 3087298 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (calcium intake: 0.55 mmol/kg/day, phosphate intake: 0.44 mmol/kg/day)
Number of subjects: 15
Study 3087298 — intervention group
Group type: COMPARATOR
Intervention: Regimen B (calcium intake: 1.08 mmol/kg/day, phosphate intake: 0.89 mmol/kg/day)
Number of subjects: 15
Study 31425538 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary end-of-life educational intervention program (two educational workshops and an educational booklet)
Number of subjects: 291
Study 31425538 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 291
Study 28080097 — intervention group
Group type: EXPERIMENTAL
Intervention: Observers judging beginner English speakers
Number of subjects: 56
Study 28080097 — intervention group
Group type: EXPERIMENTAL
Intervention: Observers judging nonnative English speakers
Number of subjects: 56
Study 26501147 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150‐300 mg/d
Number of subjects: 20
Study 26501147 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 12.5 ‐ 25 mg/d
Number of subjects: 20
Study 23240681 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-dense food enrichment (+1673 kJ day⁻¹)
Number of subjects: 41
Study 23240681 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 41
Study 21870978 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg twice daily)
Number of subjects: 18201
Study 21870978 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (target INR 2.0 to 3.0)
Number of subjects: 18201
Study 19176401 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (GHR)
Number of subjects: 7
Study 19176401 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide YY (PYY)
Number of subjects: 7
Study 17089021 — intervention group
Group type: EXPERIMENTAL
Intervention: SPS (600 mg daily)
Number of subjects: 45
Study 17089021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 15591711 — intervention group
Group type: EXPERIMENTAL
Intervention: Trofosfamide 90 mg/m2
Number of subjects: 16
Study 15591711 — intervention group
Group type: EXPERIMENTAL
Intervention: Trofosfamide 125 mg/m2
Number of subjects: 16
Study 15591711 — intervention group
Group type: EXPERIMENTAL
Intervention: Trofosfamide 175 mg/m2
Number of subjects: 16
Study 15591711 — intervention group
Group type: EXPERIMENTAL
Intervention: Trofosfamide (all doses)
Number of subjects: 16
Study 11494446 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (MT) and point massage (PM)
Number of subjects: 60
Study 11494446 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (MT), point massage (PM), and bioresonance therapy (BRT)
Number of subjects: 60
Study 10024190 — intervention group
Group type: EXPERIMENTAL
Intervention: Men >69.75 inches
Number of subjects: 6567
Study 10024190 — intervention group
Group type: EXPERIMENTAL
Intervention: Tallest men
Number of subjects: 6567
Study 10024190 — intervention group
Group type: COMPARATOR
Intervention: Women
Number of subjects: 6567
Study 7799388 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 3279083 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftifine cream 1%
Number of subjects: 104
Study 3279083 — intervention group
Group type: COMPARATOR
Intervention: Econazole cream 1%
Number of subjects: 104
Study 29742708 — intervention group
Group type: EXPERIMENTAL
Intervention: Mokhuri treatment program (Chuna, acupuncture, patient education)
Number of subjects: 0
Study 29742708 — intervention group
Group type: COMPARATOR
Intervention: Conventional nonsurgical treatments (drugs for pain relief, epidural steroid injections, physical therapy)
Number of subjects: 0
Study 27465912 — intervention group
Group type: EXPERIMENTAL
Intervention: Elcatonin (20 units, weekly intramuscular injections)
Number of subjects: 228
Study 27465912 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs (oral nonsteroidal anti-inflammatory drugs)
Number of subjects: 228
Study 26711765 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 40
Study 26711765 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline or Josamycin
Number of subjects: 40
Study 24195205 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (specific points: Sishenzhen, Zhisanzhen, Niesanzhen, Naosanzhan) for 4 months
Number of subjects: 60
Study 24195205 — intervention group
Group type: COMPARATOR
Intervention: Medication group (piracetam tablets) for 4 months
Number of subjects: 60
Study 24195205 — intervention group
Group type: COMPARATOR
Intervention: Comparison between acupuncture and medication groups
Number of subjects: 60
Study 21518561 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline for the appropriate use of antibiotics in CABG during the perioperative period
Number of subjects: 614
Study 21518561 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic antibiotic use
Number of subjects: 614
Study 19863184 — intervention group
Group type: EXPERIMENTAL
Intervention: OXY-SCORE
Number of subjects: 47
Study 19863184 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma malondialdehyde (MDA)
Number of subjects: 47
Study 19863184 — intervention group
Group type: COMPARATOR
Intervention: Cardiopulmonary bypass (CPB)
Number of subjects: 47
Study 19863184 — intervention group
Group type: COMPARATOR
Intervention: Off-pump procedure (OPCAB)
Number of subjects: 47
Study 16961161 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ketoconazole once daily on Days 1 - 4 and 5 mg SPP301 on Day 3
Number of subjects: 12
Study 16961161 — intervention group
Group type: COMPARATOR
Intervention: 5 mg SPP301 administered alone
Number of subjects: 12
Study 15093636 — intervention group
Group type: EXPERIMENTAL
Intervention: Surodex dexamethasone anterior segment drug delivery system
Number of subjects: 19
Study 15093636 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 0.1% eyedrops (Maxidex)
Number of subjects: 19
Study 11103723 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 68
Study 11103723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 9248770 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artemether (300 mg)
Number of subjects: 8
Study 9248770 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular artemether (300 mg)
Number of subjects: 8
Study 9248770 — intervention group
Group type: COMPARATOR
Intervention: Comparison of oral vs intramuscular artemether
Number of subjects: 8
Study 7834482 — intervention group
Group type: EXPERIMENTAL
Intervention: Optiray 320 (higher-strength contrast medium)
Number of subjects: 50
Study 7834482 — intervention group
Group type: COMPARATOR
Intervention: Optiray 240 (lower-strength contrast medium)
Number of subjects: 50
Study 2129004 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC (Mitomycin C)
Number of subjects: 62
Study 2129004 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating therapy with MMC and BCG (Bacillus Calmette-Guérin)
Number of subjects: 62
Study 2129004 — intervention group
Group type: COMPARATOR
Intervention: BCG
Number of subjects: 62
Study 2129004 — intervention group
Group type: COMPARATOR
Intervention: MMC
Number of subjects: 62
Study 2129004 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade of TIS
Number of subjects: 62
Study 361060 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflucortolone valerate 0.3% ointment
Number of subjects: 20
Study 361060 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol propionate 0.05% ointment
Number of subjects: 20
Study 30600865 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive telephone outcall intervention (3 outcalls from trained Cancer Council nurses)
Number of subjects: 0
Study 30600865 — intervention group
Group type: COMPARATOR
Intervention: Control group (3 phone call reminders of the availability of 131120 services)
Number of subjects: 0
Study 28759502 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block
Number of subjects: 50
Study 28759502 — intervention group
Group type: COMPARATOR
Intervention: Transversus abdominis plane block
Number of subjects: 50
Study 26218142 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem solving skills training (PSST) - 2 sessions
Number of subjects: 76
Study 26218142 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem solving skills training (PSST) - 4 sessions
Number of subjects: 76
Study 26218142 — intervention group
Group type: COMPARATOR
Intervention: Wait-list comparison group
Number of subjects: 76
Study 25536713 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (1 mA anodal)
Number of subjects: 46
Study 25536713 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo) tDCS
Number of subjects: 46
Study 22905758 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual management of malaria and pneumonia
Number of subjects: 125
Study 22905758 — intervention group
Group type: COMPARATOR
Intervention: Single management of malaria
Number of subjects: 125
Study 19752769 — intervention group
Group type: EXPERIMENTAL
Intervention: HF+PD (hemofiltration and peritoneal dialysis)
Number of subjects: 51
Study 17055216 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma experienced (n=54)
Number of subjects: 103
Study 17055216 — intervention group
Group type: COMPARATOR
Intervention: No trauma experienced (n=36)
Number of subjects: 103
Study 15749316 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-day course of intravenous antibiotic prophylaxis with ampicillin and netilmicin (two daily doses for 72 h)
Number of subjects: 130
Study 15749316 — intervention group
Group type: COMPARATOR
Intervention: Single bolus injection of intravenous antibiotic prophylaxis with ampicillin and netilmicin on admission
Number of subjects: 130
Study 15749316 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-day course of intravenous antibiotic prophylaxis with ampicillin and netilmicin
Number of subjects: 130
Study 15749316 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (three-day course and bolus)
Number of subjects: 130
Study 12131109 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at a rate to achieve a target plasma concentration of 0.5 microg/ml
Number of subjects: 10
Study 12131109 — intervention group
Group type: COMPARATOR
Intervention: 10% Intralipid or 0.9% saline (control)
Number of subjects: 10
Study 12131109 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 10
Study 10223928 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast
Number of subjects: 12
Study 10223928 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin and Clarithromycin
Number of subjects: 12
Study 8886780 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful transtibial amputees
Number of subjects: 21
Study 8886780 — intervention group
Group type: COMPARATOR
Intervention: Pain-free transtibial amputees
Number of subjects: 21
Study 1858501 — intervention group
Group type: EXPERIMENTAL
Intervention: vitamin mineral pill with a high iron content
Number of subjects: 192
Study 1858501 — intervention group
Group type: COMPARATOR
Intervention: vitamin‐mineral pill
Number of subjects: 192
Study 6353397 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg fenoterol via Hudson nebulizer
Number of subjects: 10
Study 6353397 — intervention group
Group type: COMPARATOR
Intervention: 5 mg salbutamol via Hudson nebulizer
Number of subjects: 10
Study 31618733 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 50
Study 31618733 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Number of subjects: 50
Study 31618733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 28625505 — intervention group
Group type: EXPERIMENTAL
Intervention: S-amlodipine nicotinate/olmesartan medoxomil 5/40 mg (test product)
Number of subjects: 32
Study 28625505 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besylate/olmesartan medoxomil 10/40 mg (reference product)
Number of subjects: 32
Study 28625505 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test and reference formulations
Number of subjects: 32
Study 25439179 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated training combining insufflator module and VR skills exercises
Number of subjects: 42
Study 25439179 — intervention group
Group type: COMPARATOR
Intervention: Insufflator simulation module and laparoscopic skills exercise module (control group)
Number of subjects: 42
Study 23429831 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometry
Number of subjects: 180
Study 23429831 — intervention group
Group type: COMPARATOR
Intervention: Control group (thoracic expansion exercises)
Number of subjects: 180
Study 21310897 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill Six-Minute Walk Test (Tr6MWT)
Number of subjects: 26
Study 21310897 — intervention group
Group type: COMPARATOR
Intervention: Six-Minute Walk Test (6MWT)
Number of subjects: 26
Study 19816505 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with olmesartan medoxomil (OLM) 20 mg plus azelnidipine (AZL) 16 mg (O/A (20/16))
Number of subjects: 0
Study 19816505 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with olmesartan medoxomil (OLM) 10 mg plus azelnidipine (AZL) 8 mg (O/A (10/8))
Number of subjects: 0
Study 19816505 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with olmesartan medoxomil (OLM) 20 mg (OLM (20))
Number of subjects: 0
Study 19816505 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with azelnidipine (AZL) 16 mg (AZL (16))
Number of subjects: 0
Study 16723325 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothyroidism
Number of subjects: 0
Study 16723325 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depression
Number of subjects: 0
Study 16723325 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothyroid state
Number of subjects: 0
Study 15630900 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygous AAT variants (MZ, MS, MF, ML, ME)
Number of subjects: 100
Study 15630900 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygous AAT variants
Number of subjects: 100
Study 15630900 — intervention group
Group type: COMPARATOR
Intervention: Homozygous M variant
Number of subjects: 100
Study 15630900 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary IgAN
Number of subjects: 100
Study 11378833 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA 2.5 mg
Number of subjects: 20
Study 11378833 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA 5 mg
Number of subjects: 20
Study 11378833 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA 10 mg
Number of subjects: 20
Study 11378833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11378833 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA 2.5 mg, MPA 5 mg, MPA 10 mg
Number of subjects: 20
Study 1422991 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin administration
Number of subjects: 63
Study 1422991 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse redistribution patients
Number of subjects: 63
Study 1422991 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomographic exercise thallium scintigraphy
Number of subjects: 63
Study 3989036 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml Gastrografin
Number of subjects: 50
Study 3989036 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml Gastrografin
Number of subjects: 50
Study 3989036 — intervention group
Group type: EXPERIMENTAL
Intervention: dilute barium (600 ml)
Number of subjects: 50
Study 3989036 — intervention group
Group type: COMPARATOR
Intervention: Control (no contrast medium)
Number of subjects: 50
Study 30868829 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingying Tang, 150 mL/time, twice a day for 12 weeks
Number of subjects: 72
Study 30868829 — intervention group
Group type: COMPARATOR
Intervention: Acitretin Capsules, 10 mg/time, twice a day for 12 weeks
Number of subjects: 72
Study 30868829 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study 29958726 — intervention group
Group type: EXPERIMENTAL
Intervention: Scapular muscles strengthening along with conventional physiotherapy
Number of subjects: 26
Study 29958726 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 26
Study 27294710 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional words (low-valued)
Number of subjects: 0
Study 27294710 — intervention group
Group type: COMPARATOR
Intervention: Control condition (emotional and neutral words equally valued)
Number of subjects: 0
Study 27294710 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recall performance
Number of subjects: 0
Study 25465417 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar 2.5 mg daily
Number of subjects: 20170
Study 25465417 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 20170
Study 22222512 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Education Through Simulation‐Diabetes (HPS)
Number of subjects: 16
Study 22222512 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia education enhanced with the HPS
Number of subjects: 16
Study 22222512 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument reliability demonstrated for all scales
Number of subjects: 16
Study 20462978 — intervention group
Group type: EXPERIMENTAL
Intervention: TS-1 (40-60 mg twice daily for 28 consecutive days, followed by a 14-day rest period)
Number of subjects: 600
Study 20462978 — intervention group
Group type: COMPARATOR
Intervention: Taxanes (docetaxel 60-75 mg/m(2) at 3- or 4-week intervals, paclitaxel 175 mg/m(2) at 3- or 4-week intervals or paclitaxel 80-100 mg/m(2) weekly, followed by a 1-week rest period)
Number of subjects: 600
Study 20462978 — intervention group
Group type: EXPERIMENTAL
Intervention: TS-1
Number of subjects: 600
Study 20462978 — intervention group
Group type: COMPARATOR
Intervention: Taxanes
Number of subjects: 600
Study 18227320 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation (PaCO2 = 25 +/- 2 mm Hg)
Number of subjects: 275
Study 18227320 — intervention group
Group type: COMPARATOR
Intervention: Normoventilation (PaCO2 = 37 +/- 2 mm Hg)
Number of subjects: 275
Study 16194646 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of elemental iron (liquid ferrous gluconate) for 60 days
Number of subjects: 90
Study 16194646 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of ferrous calcium citrate tablets for 60 days
Number of subjects: 90
Study 16194646 — intervention group
Group type: COMPARATOR
Intervention: 15 mg of iron for 60 days (control group)
Number of subjects: 90
Study 12651035 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP grade 2/3
Number of subjects: 267
Study 12651035 — intervention group
Group type: COMPARATOR
Intervention: Stenting
Number of subjects: 267
Study 10813100 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐FSH (Gonal‐F)
Number of subjects: 120
Study 10813100 — intervention group
Group type: COMPARATOR
Intervention: u‐FSH‐HP (Metrodin‐HP)
Number of subjects: 120
Study 8869799 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 0
Study 8869799 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 0
Study 8869799 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 0
Study 8869799 — intervention group
Group type: EXPERIMENTAL
Intervention: c-mpl-ligand (megakaryocyte growth and development factor or thrombopoietin)
Number of subjects: 0
Study 8869799 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte and granulocyte-macrophage colony-stimulating factors
Number of subjects: 0
Study 1806546 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam-beta-cyclodextrin (20 mg)
Number of subjects: 36
Study 1806546 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg)
Number of subjects: 36
Study 1806546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 1806546 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 36
Study 1806546 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam-beta-cyclodextrin
Number of subjects: 36
Study 4009328 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow‐spectrum blue light
Number of subjects: 12
Study 4009328 — intervention group
Group type: COMPARATOR
Intervention: Broad‐spectrum white light
Number of subjects: 12
Study 30122305 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.05 mg
Number of subjects: 957
Study 30122305 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.1 mg
Number of subjects: 957
Study 30122305 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.2 mg
Number of subjects: 957
Study 30122305 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.3 mg
Number of subjects: 957
Study 30122305 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.4 mg
Number of subjects: 957
Study 30122305 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 957
Study 30122305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 957
Study 30122305 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide (0.1 mg or more)
Number of subjects: 957
Study 26639678 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine/naloxone (BNX)
Number of subjects: 102
Study 26639678 — intervention group
Group type: COMPARATOR
Intervention: Oral naltrexone (NTX)
Number of subjects: 102
Study 23561959 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived stem cell transplantation (ABMSCT)
Number of subjects: 21